NZ628963A - Transmucosal delivery of tocotrienol - Google Patents

Transmucosal delivery of tocotrienol

Info

Publication number
NZ628963A
NZ628963A NZ628963A NZ62896313A NZ628963A NZ 628963 A NZ628963 A NZ 628963A NZ 628963 A NZ628963 A NZ 628963A NZ 62896313 A NZ62896313 A NZ 62896313A NZ 628963 A NZ628963 A NZ 628963A
Authority
NZ
New Zealand
Prior art keywords
tocotrienol
muscle soreness
transmucosal delivery
delivery
baldness
Prior art date
Application number
NZ628963A
Other languages
English (en)
Inventor
Glenn Tong
Original Assignee
Gordagen Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012904937A external-priority patent/AU2012904937A0/en
Application filed by Gordagen Pharmaceuticals Pty Ltd filed Critical Gordagen Pharmaceuticals Pty Ltd
Publication of NZ628963A publication Critical patent/NZ628963A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ628963A 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol NZ628963A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2012904937A AU2012904937A0 (en) 2012-11-13 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
AU2012905406A AU2012905406A0 (en) 2012-12-11 Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents
PCT/AU2013/001310 WO2014075135A1 (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Publications (1)

Publication Number Publication Date
NZ628963A true NZ628963A (en) 2017-02-24

Family

ID=50730398

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ628963A NZ628963A (en) 2012-11-13 2013-11-13 Transmucosal delivery of tocotrienol

Country Status (22)

Country Link
US (2) US10675265B2 (enExample)
EP (1) EP2919777B1 (enExample)
JP (3) JP6460998B2 (enExample)
KR (1) KR20150082109A (enExample)
CN (2) CN104582700B (enExample)
AU (1) AU2013344817B2 (enExample)
BR (1) BR112015010703B1 (enExample)
CA (1) CA2891164C (enExample)
DK (1) DK2919777T3 (enExample)
ES (1) ES2778065T3 (enExample)
IL (1) IL238727A0 (enExample)
IN (1) IN2015DN04006A (enExample)
MY (1) MY177940A (enExample)
NZ (1) NZ628963A (enExample)
PE (1) PE20151518A1 (enExample)
PH (1) PH12015501048A1 (enExample)
PL (1) PL2919777T3 (enExample)
PT (1) PT2919777T (enExample)
RU (1) RU2015120181A (enExample)
SG (1) SG11201503640WA (enExample)
WO (1) WO2014075135A1 (enExample)
ZA (1) ZA201504191B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
RU2015120181A (ru) * 2012-11-13 2017-01-10 Гордаген Фармасьютикалз Пти Лтд Чресслизистая доставка токотриенола
US9233204B2 (en) 2014-01-31 2016-01-12 Aseko, Inc. Insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
AU2015339576B2 (en) 2014-10-27 2020-02-06 Glytec, Llc Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
WO2017025808A1 (en) * 2015-08-11 2017-02-16 Satoru Sugiyama System and method for improved blood circulation and maintaining mitochondrial energy production
EP3337402A4 (en) 2015-08-20 2019-04-24 Aseko, Inc. THERAPY ADVISOR FOR DIABETES MANAGEMENT
US11612613B2 (en) 2017-08-08 2023-03-28 Robert Petcavich Formulations for the delivery of autophagy stimulating Trehalose
US20240139100A1 (en) * 2020-12-04 2024-05-02 Invictus Biotechnology Pty Ltd Transmucosal delivery of tocotrienols

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2124086A1 (en) * 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
JPH0892050A (ja) 1994-09-27 1996-04-09 Lion Corp 消臭剤及び口腔用組成物
JP4271742B2 (ja) 1997-08-07 2009-06-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫機能改善剤
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6864280B2 (en) * 2000-03-31 2005-03-08 Eisai Co., Ltd. γ-Tocotrienol-containing diuretics
JP2001342133A (ja) 2000-03-31 2001-12-11 Eisai Co Ltd γ―トコトリエノール含有利尿剤
JP2002037727A (ja) 2000-07-26 2002-02-06 Eisai Co Ltd 脂溶性薬物を配合した速崩性固形製剤及びその製造方法
JP4693140B2 (ja) 2000-10-06 2011-06-01 富士化学工業株式会社 トコトリエノール含有医薬用剤
JP4447198B2 (ja) 2001-02-08 2010-04-07 富士化学工業株式会社 トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物
US6608103B2 (en) * 2001-02-08 2003-08-19 Fuji Chemical Industry Co., Ltd. Inhibitor for neovasculation, cell multiplication, lumen formation and FGF
WO2004086412A2 (en) 2003-02-14 2004-10-07 Henry M. Jackson Foundation For The Advancement Of Military Medecine, Inc. Radiation protection by gamma-tocotrienol
CA2521020C (en) * 2003-04-10 2021-04-27 Barrie Tan Annatto extract compositions including tocotrienols and tocopherols and methods of use
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
US20060013901A1 (en) * 2004-05-26 2006-01-19 Kgk Synergize Inc. Compositions comprising flavonoids and tocotrienols and methods thereof
CN1775289B (zh) 2004-11-15 2011-08-24 杭州赛诺菲民生健康药业有限公司 多维生素口腔崩解片制剂及其制备方法
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
WO2009126866A2 (en) * 2008-04-10 2009-10-15 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Delta-tocotrienol as a radioprotective countermeasure agent
MX2011012078A (es) 2009-05-20 2012-03-14 Lingual Consegna Pty Ltd Formulacion terapeutica bucal y/o sublingual.
EA201200054A1 (ru) 2009-06-25 2012-05-30 Эмпэр Лайф Сайнсиз, Инк. Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
HUE037592T2 (hu) * 2009-08-26 2018-09-28 Bioelectron Tech Corp Eljárások cerebrális ischemia megelõzésére és kezelésére
EP2519232A1 (en) 2009-12-31 2012-11-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
EA201201374A1 (ru) * 2010-04-06 2013-04-30 Эдисон Фармасьютикалз, Инк. Лечение атаксии-телеангиэктазии
WO2012068552A1 (en) * 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
KR101796340B1 (ko) 2011-02-18 2017-11-10 바이오링거스 아이피 엘엘씨 안정화된 활성제를 포함하는 생성물을 제조하는 방법 및 이를 포함하는 조성물
EP2720699B1 (en) 2011-06-14 2018-05-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine
RU2015120181A (ru) * 2012-11-13 2017-01-10 Гордаген Фармасьютикалз Пти Лтд Чресслизистая доставка токотриенола

Also Published As

Publication number Publication date
JP6978392B2 (ja) 2021-12-08
JP6460998B2 (ja) 2019-01-30
MY177940A (en) 2020-09-28
PL2919777T3 (pl) 2020-07-13
BR112015010703A2 (pt) 2017-07-11
US20150265570A1 (en) 2015-09-24
PT2919777T (pt) 2020-03-30
CA2891164C (en) 2021-02-09
SG11201503640WA (en) 2015-06-29
US10675265B2 (en) 2020-06-09
EP2919777A1 (en) 2015-09-23
AU2013344817A1 (en) 2015-02-12
CN112451518B (zh) 2025-02-21
ZA201504191B (en) 2016-11-30
BR112015010703A8 (pt) 2018-08-14
US20200246306A1 (en) 2020-08-06
DK2919777T3 (da) 2020-03-09
IN2015DN04006A (enExample) 2015-10-02
PE20151518A1 (es) 2015-11-25
RU2015120181A (ru) 2017-01-10
CN104582700B (zh) 2021-01-05
BR112015010703B1 (pt) 2021-02-17
WO2014075135A1 (en) 2014-05-22
JP2019031504A (ja) 2019-02-28
PH12015501048A1 (en) 2015-07-27
EP2919777A4 (en) 2016-05-18
CN104582700A (zh) 2015-04-29
EP2919777B1 (en) 2020-01-08
JP2016503407A (ja) 2016-02-04
IL238727A0 (en) 2015-06-30
ES2778065T3 (es) 2020-08-07
CA2891164A1 (en) 2014-05-22
KR20150082109A (ko) 2015-07-15
HK1207295A1 (en) 2016-01-29
US11331302B2 (en) 2022-05-17
AU2013344817B2 (en) 2015-09-17
JP2021008509A (ja) 2021-01-28
CN112451518A (zh) 2021-03-09

Similar Documents

Publication Publication Date Title
NZ628963A (en) Transmucosal delivery of tocotrienol
HUS2100039I1 (hu) Készítmények és eljárások trigliceridek csökkentésére az LDL-C szintek emelése nélkül egy alanynak sztatin terápiájában
MY187988A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
UY32820A (es) Composiciones dermatologicas de antagonistas del receptor dp2
WO2008116024A3 (en) Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
EA201190219A1 (ru) Способы и композиции для лечения ишемических состояний и состояний, связанных с функцией митохондрий
CZ308507B6 (cs) Parazitické orální veterinární kompozice obsahující systémově působící aktivní činidla, způsoby a jejich použití
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
CR20110596A (es) Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
JP2016503407A5 (enExample)
EP2853543A8 (en) Anti-blys antibody
MX2011011596A (es) Perifosina y capecitabina como un tratamiento combinado para cancer.
CR11600A (es) Derivados de indazol
IL220894A (en) Combinations of active substances containing dihydroporone and abamctin
WO2011104652A3 (en) Veterinary compositions
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
GB2489382A (en) Azetidine derivatives useful for the treatment of metabolic and inflammatory diseases
MX2012013478A (es) Composicion para evitar perdida del cabello o estimular crecimiento del cabello.
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
EP2575456A4 (en) COMPOSITIONS AND METHODS FOR TREATING PRESENTATIONS
GEP20146123B (en) ) usage of 4-[ethyl (dimethyl) ammonio] butanoate in treatment of cardiovascular disease
CL2013001445A1 (es) Compuestos derivados de difenilamina; composicion farmaceutica y uso en el tratamiento de enfermedades inflamatorias, tales como cancer.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2018 BY FB RICE PTY LTD

Effective date: 20171110

ASS Change of ownership

Owner name: INVICTUS BIOTECHNOLOGY PTY LTD, AU

Effective date: 20180411

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2019 BY FB RICE PTY LTD

Effective date: 20181031

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2020 BY FB RICE PTY LTD

Effective date: 20191108

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2021 BY FB RICE PTY LTD

Effective date: 20201030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2022 BY FB RICE PTY LTD

Effective date: 20211015

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2023 BY FB RICE PTY LTD

Effective date: 20221014

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2024 BY FB RICE PTY LTD

Effective date: 20231013

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2025 BY FB RICE PTY LTD

Effective date: 20241030

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 NOV 2026 BY FB RICE PTY LTD

Effective date: 20251105